Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia.

de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N.

Blood. 2017 Jan 17. pii: blood-2016-06-724500. doi: 10.1182/blood-2016-06-724500. [Epub ahead of print] No abstract available.

PMID:
28096091
2.

Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO).

Todisco E, Ciceri F, Boschini C, Giglio F, Bacigalupo A, Patriarca F, Donnini I, Alessandrino EP, Arcese W, Iori AP, Marenco P, Cavattoni I, Chiusolo P, Terruzzi E, Castagna L, Santoro A, Bosi A, Oldani E, Bruno B, Bonifazi F, Rambaldi A.

Bone Marrow Transplant. 2017 Jan 9. doi: 10.1038/bmt.2016.325. [Epub ahead of print]

PMID:
28067875
3.

Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission.

Saraceni F, Bruno B, Lemoli RM, Meloni G, Arcese W, Falda M, Ciceri F, Alessandrino EP, Specchia G, Scimè R, Raimondi R, Bacigalupo A, Bosi A, Onida F, Rambaldi A, Bonifazi F, Olivieri A.

Bone Marrow Transplant. 2017 Jan;52(1):163-166. doi: 10.1038/bmt.2016.233. No abstract available.

PMID:
27668760
4.

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M.

J Clin Oncol. 2016 Sep 6. pii: JCO673616. [Epub ahead of print]

PMID:
27601546
5.

Neurological Complications Involving the Central Nervous System After Allogeneic Hematopoietic Stem Cell Transplantation During a Period of Evolution in Transplant Modalities: A Cohort Analysis.

Colombo AA, Marchioni E, Diamanti L, Di Matteo AM, Baldanti F, Furione M, Cazzola M, Ferretti VV, Pascutto C, Alessandrino EP.

Transplantation. 2016 May 24. [Epub ahead of print]

PMID:
27222935
6.

Novel trial designs for high-risk myelodysplastic syndromes.

Alessandrino EP, Porta MG.

Lancet Oncol. 2016 Apr;17(4):410-2. doi: 10.1016/S1470-2045(16)00073-5. No abstract available.

PMID:
26968356
7.

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.

Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A.

Lancet Oncol. 2015 Nov;16(15):1525-36. doi: 10.1016/S1470-2045(15)00200-4.

PMID:
26429297
8.

Reconstitution of Human Cytomegalovirus-Specific CD4+ T Cells is Critical for Control of Virus Reactivation in Hematopoietic Stem Cell Transplant Recipients but Does Not Prevent Organ Infection.

Gabanti E, Lilleri D, Ripamonti F, Bruno F, Zelini P, Furione M, Colombo AA, Alessandrino EP, Gerna G.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2192-202. doi: 10.1016/j.bbmt.2015.08.002.

9.

Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma.

Arcaini L, Morello L, Tucci A, Rusconi C, Ladetto M, Rattotti S, Bonfichi M, Bottelli C, Gabutti C, Bernasconi P, Varettoni M, Gotti M, Troletti D, Guerrera ML, Fiaccadori V, Sciarra R, Ferretti VV, Alessandrino EP, Rossi G, Morra E.

Am J Hematol. 2015 Mar;90(3):230-4. doi: 10.1002/ajh.23919.

10.

Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from human leukocyte antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party.

Onida F, Brand R, van Biezen A, Schaap M, von dem Borne PA, Maertens J, Beelen DW, Carreras E, Alessandrino EP, Volin L, Kuball JH, Figuera A, Sierra J, Finke J, Kröger N, de Witte T; MDS subcommittee of the EBMT-CMWP..

Haematologica. 2014 Oct;99(10):1582-90. doi: 10.3324/haematol.2014.106880.

11.

Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.

Della Porta MG, Alessandrino EP.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1260-1. doi: 10.1016/j.bbmt.2014.07.006. No abstract available.

12.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo..

Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720.

13.

Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?

Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A.

J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. No abstract available.

PMID:
23775971
14.

Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.

Spierings E, Kim YH, Hendriks M, Borst E, Sergeant R, Canossi A, Oudshoorn M, Loiseau P, Dolstra H, Markiewicz M, Leffell MS, Pereira N, Kircher B, Turpeinen H, Eliaou JF, Gervais T, Laurin D, Enczmann J, Martinetti M, Thomson J, Oguz F, Santarone S, Partanen J, Siekiera U, Alessandrino EP, Kalayoglu S, Brand R, Goulmy E.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1244-53. doi: 10.1016/j.bbmt.2013.06.001.

15.

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation.

Martínez C, Canals C, Sarina B, Alessandrino EP, Karakasis D, Pulsoni A, Sica S, Trneny M, Snowden JA, Kanfer E, Milpied N, Bosi A, Guidi S, de Souza CA, Willemze R, Arranz R, Jebavy L, Hellmann A, Sibon D, Oneto R, Luan JJ, Dreger P, Castagna L, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)..

Ann Oncol. 2013 Sep;24(9):2430-4. doi: 10.1093/annonc/mdt206.

PMID:
23712545
16.

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome.

Alessandrino EP, Porta MG, Malcovati L, Jackson CH, Pascutto C, Bacigalupo A, Teresa van Lint M, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Rambaldi A, Bosi A, Cazzola M; Gruppo Italiano Trapianto di Midollo Osseo (GITMO)..

Am J Hematol. 2013 Jul;88(7):581-8. doi: 10.1002/ajh.23458.

17.

Infection and coinfection of human rhinovirus C in stem cell transplant recipients.

Canducci F, Debiaggi M, Ceresola ER, Sampaolo M, Alessandrino EP, Brerra R, Piazza A, Clementi M.

Clin Dev Immunol. 2013;2013:236081. doi: 10.1155/2013/236081.

18.

Differential outcome of neurological HCMV infection in two hematopoietic stem cell transplant recipients.

Colombo AA, Giorgiani G, Rognoni V, Villani P, Furione M, Bonora MR, Alessandrino EP, Zecca M, Baldanti F.

BMC Infect Dis. 2012 Oct 3;12:238. doi: 10.1186/1471-2334-12-238.

19.

Epidemiological, molecular and clinical features of enterovirus 109 infection in children and in adult stem cell transplant recipients.

Debiaggi M, Ceresola ER, Sampaolo M, Alessandrino EP, Brerra R, Piazza A, Clementi M, Canducci F.

Virol J. 2012 Sep 4;9:183. doi: 10.1186/1743-422X-9-183.

20.

Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo.

Alessandrino EP, Angelucci E, Cazzola M, Porta MG, Di Bartolomeo P, Gozzini A, Malcovati L, Pioltelli P, Sica S, Bosi A.

Am J Hematol. 2011 Oct;86(10):897-902. doi: 10.1002/ajh.22104. No abstract available.

Items per page

Supplemental Content

Loading ...
Support Center